Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
In this randomized trial, we will investigate the activity and toxicity of two active
regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by
ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Phase:
Phase 3
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
AstraZeneca Eli Lilly and Company Pharmacia and Upjohn